Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
“The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
The vascular endothelium is a highly specialized, metabolically active organ that plays a pivotal role in cardiovascular homeostasis. It regulates vascular tone, platelet activity, leukocyte adhesion, oxidative balance, and thrombosis primarily through the synthesis of vasoactive mediators, notably nitric oxide (NO). In healthy individuals, endothelial cells maintain high NO bioavailability, which promotes vasodilation, inhibits smooth muscle proliferation, suppresses inflammation, and prevents platelet aggregation.
Epidemiological and mechanistic studies consistently demonstrate that endothelial dysfunction precedes overt atherosclerosis by decades. Flow-mediated dilation (FMD), a validated marker of endothelial function, declines progressively with age—approximately 0.5–1.0% per decade in low-risk populations—and is markedly impaired in individuals with traditional cardiovascular risk factors. Large cohort studies show that a 1% reduction in FMD is associated with an 8–13% increase in future cardiovascular events.
Reduced NO bioavailability is a hallmark of endothelial dysfunction and is strongly linked to atherosclerotic progression. Experimental and clinical data indicate that NO production may decline by 40–60% in middle-aged adults with metabolic syndrome or diabetes, accelerating lipid oxidation, vascular inflammation, and plaque formation. In advanced stages, severe NO depletion (<20% of physiological levels) is associated with arterial stiffening, plaque instability, and a significantly increased risk of thrombotic events.
Clinically, endothelial dysfunction independently predicts myocardial infarction, stroke, and cardiovascular mortality, even after adjustment for conventional risk factors. Meta-analyses involving over 20,000 patients demonstrate that impaired endothelial function confers a 1.7–2.3-fold higher risk of major adverse cardiovascular events. These findings underscore that endothelial health is not merely a marker but a central driver of cardiovascular disease complexity, progression, and clinical outcomes—making it a critical therapeutic target in modern preventive cardiology.”
More posts featuring Ney Carter Borges.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers